Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study.

@article{Ledwidge2015CosteffectivenessON,
  title={Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study.},
  author={Mark T. Ledwidge and Eoin O’Connell and Joseph J Gallagher and Lesley Tilson and Stephanie I. James and Victor Voon and Margaret Bermingham and Elaine Tallon and Chris J. Watson and Rory O'Hanlon and Michael G. Barry and K. Mcdonald},
  journal={European journal of heart failure},
  year={2015},
  volume={17 7},
  pages={
          672-9
        }
}
AIMS Prevention of cardiovascular disease and heart failure (HF) in a cost-effective manner is a public health goal. This work aims to assess the cost-effectiveness of the St Vincent's Screening TO Prevent Heart Failure (STOP-HF) intervention. METHODS AND RESULTS This is a substudy of 1054 participants with cardiovascular risk factors [median age 65.8 years, interquartile range (IQR) 57.8:72.4, with 4.3 years, IQR 3.4:5.2, follow-up]. Annual natriuretic peptide-based screening was performed… CONTINUE READING
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

How peptide technology has improved costs and outcomes in patients with heart failure.

  • Expert review of pharmacoeconomics & outcomes research
  • 2016
VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

World Heart Federation Roadmap for Heart Failure.

  • Global heart
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND & METHODS